Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof

Abstract

The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions ═CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.

1 - 16 . (canceled)  
   
   
       17 . A chimeric monoclonal antibody comprising variable V H  and V K  regions wherein said V H  and V K  regions comprise the amino acid sequences shown in  FIG. 6  and in which the constant regions are human antibody amino acid sequences.  
   
   
       18 . The monoclonal antibody as claimed in  claim 17 , wherein enzymes or radioactive labels are coupled to the antibody.  
   
   
       19 . The monoclonal antibody as claimed in  claim 17 , wherein the antibody is coupled to toxins, catalytic antibodies, combinations of V genes of various specificities, MHC class I antigens or MHC class II antigens, or cytolytic components.  
   
   
       20 . A pharmaceutical composition comprising the monoclonal antibody as claimed in  claim 17  in a pharmaceutically acceptable carrier.  
   
   
       21 . A monoclonal antibody as claimed in  claim 17  for use in vivo or in vitro diagnosis.  
   
   
       22 . A therapeutic composition comprising the antibody as claimed in  claim 17  and an inert vehicle.  
   
   
       23 . The monoclonal antibody as claimed in  claim 17 , wherein the variable regions have amino acid sequences shown in  FIG. 6 .  
   
   
       24 . A method of producing the monoclonal antibody as claimed in  claim 17  comprising: 
 (a) preparing DNA encoding said variable regions and said regions outside of the variable regions containing human antibody amino acid sequences and amplifying said DNA via polymerase chain reaction (PCR) using TAQ polymerase and PCR primers from cDNA isolated from hybridomas;    (b) expressing said DNA to produce said antibody; and    (c) isolating said antibody.